Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Incidence of COVID-19 in patients under chronic treatment with hydroxychloroquine
Cifuentes et al., Medicina Clínica (English Edition), doi:10.1016/j.medcle.2020.10.012
Cifuentes et al., Incidence of COVID-19 in patients under chronic treatment with hydroxychloroquine, Medicina Clínica (English Edition), doi:10.1016/j.medcle.2020.10.012
Jan 2021   Source   PDF  
  All Studies   Meta
Retrospective 3,817 chronic HCQ patients showing 4.4% COVID-19 positive rate, 1.3% severe. There is no comparison with a control group. Authors note that there was a 3.6% incidence among 2,032,863 patients in one of the regions (Castilla La Mancha), however they provide no information on this group - it is expected that the mostly systemic autoimmune disease patients in the treatment group are older on average. Additonally, other research shows that the risk of COVID-19 for systemic autoimmune disease patients is much higher overall, Ferri et al. show OR 4.42, p<0.001 [Ferri].
Cifuentes et al., 23 Jan 2021, peer-reviewed, 18 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Med Clin (Barc). 2021;156(4):166–171 Original article Incidence of COVID-19 in patients under chronic treatment with hydroxychloroquine夽 Francisco Tejada Cifuentes a,∗ , Ángeles Lloret Callejo a , María José Tirado Peláez a , Olga Rubio Pulido b , Marta Ruiz-Morote Aragón c , Rocío Fernández Urrusuno d , María Isabel Muñoz Carreras e , María Isabel Méndez Esteban f , Victoria Maestre Sánchez g , Antonio García Bonilla h , José Manuel Paredero Dominguez i , Virginia Arroyo Pineda j , Esther Marco Tejón k , Gregorio Romero Candel l , Ana Isabel Fernández Marchante m , José Marco del Rio n , Teresa Ortiz Martín o , Piedad López Sánchez p a Gerencia de Atención Integrada de Albacete, Albacete, Spain Gerencia de Atención Primaria de Toledo, Toledo, Spain c Gerencia de Atención Integrada de Puertollano, Puertollan, Spain d Distrito Sanitario Aljarafe, Sevilla, Spain e Gerencia de Atención Integrada, Alcázar de San Juan, Alcázar de San Juan, Spain f Área de Gestión Sanitaria Campo de Gibraltar, Cádiz, Spain g Distrito Sanitario Condado Campiña, Huelva, Spain h Área de Gestión Sanitaria Jerez, Costa Noroeste y Sierra de Cádiz, Jerez, Spain i Gerencia de Atención Integrada, de Guadalajara, Guadalajara, Spain j Gerencia de Atención Integrada Talavera de la Reina, Talavera de la Reina, Spain k Gerencia de Atención Integrada de Cuenca, Cuenca, Spain l Gerencia de Atención Integrada de Hellín, Hellín, Spain m Gerencia de Atención Integrada de Villarrobledo, Villarrobledo, Spain n Gerencia de Atención Integrada de Almansa, Almansa, Spain o Gerencia de Atención Integrada de Valdepeñas, Valdepeñas, Spain p Gerencia de Atención Integrada de Tomelloso, Tomelloso, Spain b a r t i c l e i n f o Article history: Received 22 August 2020 Accepted 16 October 2020 Available online 23 January 2021 Keywords: COVID-19 Coronavirus Incidence Hydroxychloroquine Treatment a b s t r a c t Objective: To analyze the incidence of Covid-19 in patients who are chronic users of hydroxychloroquine. Patients and methods: Cross-sectional retrospective observational multicenter study in health areas and districts from Castilla La-Mancha and Andalucia. Of the 4451 participants included in the first recruitment, 3817 with valid data were selected. The main variable of the study is the presence or absence of Covid-19 infection by clinical, serological or polymerase chain reaction diagnosis. Sociodemographic and clinical variables and treatment and concomitant comorbidities were recorded. Results: 169 (4,45%) patients had Covid-19 infection, of which 12 (7.1 %) died and 32 (18.9%) required hospital admission. Previous respiratory pathology was related to Covid-19 infection (P < .05). Maculopathy appears in 5.3% of patients and is significantly related to the dose of hydroxychloroquine consumed (P < .05). Conclusion: There is no relationship between chronic use of hydroxychloroquine and the incidence of Covid-19. © 2020 Elsevier España, S.L.U. All rights reserved. 夽 Please cite this article as: Tejada Cifuentes F, Lloret Callejo Á, Tirado Peláez MJ, Rubio Pulido O, Ruiz-Morote Aragón M, Fernández Urrusuno R, et al. Incidencia de la COVID-19 en pacientes en tratamiento crónico con hidroxicloroquina. Med Clin (Barc). 2021;156:166–171. ∗ Corresponding author. E-mail address: (F. Tejada Cifuentes). 2387-0206/© 2020 Elsevier España, S.L.U. All rights reserved. F. Tejada Cifuentes et al. / Med Clin (Barc)...
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop